ARCH Venture Partners: €4.6M-€46M checks, Seed to Series A
- Check size
- €4.6M – €46M
Investment thesis
With $12B in total AUM, ARCH is one of the largest biotech venture firms globally, creating and funding companies around the most promising scientific breakthroughs.
How to Pitch ARCH Venture Partners
No stated policy
ARCH Venture Partners hasn't published an outreach policy. A short, specific cold email is the safest default.
Who to contact
Ari Nowacek
Partner
Axel Bouchon
Venture Partner
Recent investments
Auto-extracted from press releases.
- Series A · 2 Oct 2026
- Seed · 25 Jun 2026
- Seed · 23 Feb 2026
Activity trend
Light dataLast 90d
1
Prior 90d
1
Year ago
0
Portfolio highlights
Alnylam Pharmaceuticals - RNAi therapeutics
GRAIL - multi-cancer early detection
Impinj - IoT/RAIN RFID
Partners
Auto-detected from ARCH Venture Partners's website.
Similar investors
Focus and check size from the firm's website. Website reachable as of Nov 2026.
Ready to reach ARCH Venture Partners?
Red-pen your deck first so the gaps are fixed before they read it. A fit check then scores your pitch against their thesis, stage and ticket, and an email draft uses their real deals and thesis, not a template.
Contact
archventure.com
Reach ARCH Venture Partners through the links above. Pitchkit is not affiliated with the firm and does not forward pitches.